Abstract
Memantine, an aminodamantane, has recently been approved to treat moderate-to-severe Alzheimers disease in the US after over 20 years on the market in Europe for treatment of Parkinsons disease. The unique properties of Memantine allow for its selective inhibition of abnormally active NMDA receptor channels while preserving normal glutamate activity and healthy neuronal function. Recently, it has been shown that compounds such as nitroglycerin, used for years for ischemic coronary disease, can also regulate the NMDA receptor channel. Novel compounds have been synthesized in an attempt to combine these activities, in an attempt to synergistically improve upon the activities of both nitrates and aminoadamantanes. We have subjected these compounds to several laboratory tests to compare their ability to affect the function of the NMDA receptor and to dilate blood vessels. These tests provide an initial indication of which of the compounds may have enhanced activity relative to memantine. The results also provide guidance for the synthesis of additional compounds that are likely to have the properties that are being sought.
Keywords: NMDA receptor, S-nitrosothiol, Electrophysiology, memantine-binding domain, open-channel block
Current Alzheimer Research
Title: The Pharmacology of Aminoadamantane Nitrates
Volume: 3 Issue: 3
Author(s): Yuqiang Wang, Jerry Eu, Mark Washburn, Tong Gong, H.-S. Vincent Chen, W. Larrick James, Stuart A. Lipton, Jonathan S. Stamler, Gregory T. Went and Seth Porter
Affiliation:
Keywords: NMDA receptor, S-nitrosothiol, Electrophysiology, memantine-binding domain, open-channel block
Abstract: Memantine, an aminodamantane, has recently been approved to treat moderate-to-severe Alzheimers disease in the US after over 20 years on the market in Europe for treatment of Parkinsons disease. The unique properties of Memantine allow for its selective inhibition of abnormally active NMDA receptor channels while preserving normal glutamate activity and healthy neuronal function. Recently, it has been shown that compounds such as nitroglycerin, used for years for ischemic coronary disease, can also regulate the NMDA receptor channel. Novel compounds have been synthesized in an attempt to combine these activities, in an attempt to synergistically improve upon the activities of both nitrates and aminoadamantanes. We have subjected these compounds to several laboratory tests to compare their ability to affect the function of the NMDA receptor and to dilate blood vessels. These tests provide an initial indication of which of the compounds may have enhanced activity relative to memantine. The results also provide guidance for the synthesis of additional compounds that are likely to have the properties that are being sought.
Export Options
About this article
Cite this article as:
Wang Yuqiang, Eu Jerry, Washburn Mark, Gong Tong, Vincent Chen H.-S., Larrick James W., Lipton A. Stuart, Stamler S. Jonathan, Went T. Gregory and Porter Seth, The Pharmacology of Aminoadamantane Nitrates, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632808
DOI https://dx.doi.org/10.2174/156720506777632808 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Models of Change in Schizophrenia: One for All, or All for Some?
Current Psychiatry Reviews Alzheimers Disease: Targets For Drug Development
Mini-Reviews in Medicinal Chemistry An Introduction to Obesity and Dementia
Current Alzheimer Research QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres
Current Topics in Medicinal Chemistry GABAA Receptor Subtype Selective Cognition Enhancers
Current Drug Targets - CNS & Neurological Disorders The Alzheimer's Disease-Related Glucose Metabolic Brain Pattern
Current Alzheimer Research The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Drug Choices and Advancements for Managing Depression in Parkinson's Disease
Current Neuropharmacology Recent Topics on Pharmacotherapy for Amphetamine-Type Stimulants Abuse and Dependence
Current Drug Abuse Reviews Alzheimer’s Disease – Future Therapy Based on Dendrimers
Current Neuropharmacology Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
CNS & Neurological Disorders - Drug Targets Involvement of the Serotonergic System in Cognitive and Behavioral Symptoms of Alzheimers Disease
Current Psychiatry Reviews Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers
Current Medicinal Chemistry α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease
Current Alzheimer Research Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Current Pharmaceutical Design Ocular Biomarkers of Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry